What is the purpose of Bortezomib 3.5 mg Injection?
Multiple myeloma is treated with the medication Bortezomib 3.5 mg Injection (a type of cancer of the bone marrow). Bortezomib is also used to treat mantle cell lymphoma patients (fast-growing cancer that begins in the cells of the immune system). Bortezomib belongs to the class of medicines known as antineoplastic agents.
Is bortezomib a type of chemotherapy?
Bortezomib is a proteasome inhibitor, which is a type of cancer treatment medicine. Cells contain proteasomes. They assist in the breakdown of proteins that the cell does not require. Bortezomib inhibits the proteasomes, causing proteins to accumulate inside the cell.
What are the Bortezomib 3.5 mg Injection side effects?
- The injection site may cause dizziness
- lack of appetite
- or pain/redness.
- and diarrhea is all common side effects. to know more see click here
What is the best way to utilize bortezomib injection?
It is injected once or twice weekly, for variable durations of time, into a vein (intravenously) or beneath the skin (subcutaneously), depending on the ailment being treated. Each Bortezomib 3.5 mg Injection dose should be separated by at least 72 hours. This drug must be handled with extreme caution.
What is the best way to dilute bortezomib injection?
2.5 mg/ml Bortezomib 3.5 mg Injection After diluting the Solution for Injection to 1 mg/ml (see section 6.6), it is given as a 3-5 second bolus intravenous injection by a peripheral or central intravenous catheter, followed by a flush with sodium chloride 9 mg/ml (0.9 percent) solution for injection.
Is bortezomib an oral medication?
According to data from a mid-stage study presented at the 54th Annual Meeting of the American Society of Hematology in Atlanta, Georgia, the investigational oral proteasome inhibitor MLN9708—which is a new version of Velcade® (bortezomib)—may be more effective and well-tolerated than Velcade injections.
How frequently is Bortezomib 3.5 mg Injection administered?
VELCADE is given twice weekly for two weeks (Days 1, 4, 8, and 11), then a ten-day break from Days 12 to 21. Two further VcR-CAP cycles are indicated for patients who had a response at cycle 6. Between successive VELCADE doses, at least 72 hours should pass.